Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy
Cancer · 2025
DOI: 10.1002/cncr.35652 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Lu Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, C…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Patient Reported Outcome Measures, Protein Kinase Inhibitors, Quality of Life. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The objective of this study was to assess patient‐reported outcomes (PROs), including health‐related quality of life (HRQoL) and anxiety and depression symptoms, and to identify associated variables in patients with tyrosine kinase inhibitor (TKI)‐resistant chronic myeloid leukemia (CML) in chronic‐phase (CP) or accelerated‐phase (AP) who were receiving olverembatinib.
Methods
Patients in multicenter studies were invited to complete the European Organization for Research and Treatment of Cancer Quality‐of‐Life Core 30 Questionnaire, the Self‐Rating Anxiety Scale, and the Self‐Rating Depression Scale at baseline and regularly during olverembatinib therapy. The time trends in PROs were estimated with a linear model using a generalized estimating equation based on an independent working correlation matrix. A generalized estimating equation model was used to assess the variables associated with PROs.
Results
In total, 146 patients with CML‐CP or CML‐AP were included in this study. Scores on seven items from the European Organization for Research and Treatment of Cancer Quality‐of‐Life Core 30 Questionnaire, including global health, physical functioning, emotional functioning, fatigue, dyspnea, diarrhea, and financial difficulties, improved significantly over time during olverembatinib therapy. In multivariate analysis, age younger than 40 years was significantly associated with greater improvement in social functioning ( p = .033), and CML‐CP (vs. CML‐AP) was associated with greater improvements in dyspnea ( p = .031) and diarrhea ( p = .031) over time. Scores on the Self‐Rating Anxiety Scale and the Self‐Rating Depression Scale decreased significantly over time during olverembatinib treatment ( p < .001).
Conclusions
The authors concluded that HRQoL significantly improved over time during olverembatinib therapy in heavily treated patients with TKI‐resistant CML, especially among those who were younger and those who had CML‐CP. Anxiety symptoms also significantly decreased over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Lu Yu, Weiming Li, Yu Hu, Qian Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yu, L., Li, W., Xu, N., Liu, X., Liu, B., Zhang, Y., Meng, L., Zhu, H., Du, X., Chen, S., Hu, Y., Song, Y., Men, L., & Jiang, Q. (2025). Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer. https://doi.org/10.1002/cncr.35652
Vancouver
Yu L, Li W, Xu N, Liu X, Liu B, Zhang Y, et al. Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer. 2025. doi:10.1002/cncr.35652
BibTeX
@article{Yu2025,
author = {Yu, Lu and Li, Weiming and Xu, Na and Liu, Xiaoli and Liu, Bingcheng and Zhang, Yanli and Meng, Li and Zhu, Huanling and Du, Xin and Chen, Suning and Hu, Yu and Song, Yongping and Men, Lichuang and Jiang, Qian},
title = {Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35652}
}
EUVIMED